| Line 182: | Line 182: | ||
*Citation: Critcher, C. R., & Siegel, M. (2021). Re-examining the Association Between E-Cigarette Use and Myocardial Infarction: A Cautionary Tale. American journal of preventive medicine, 61(4), 474–482. https://doi.org/10.1016/j.amepre.2021.05.003 | *Citation: Critcher, C. R., & Siegel, M. (2021). Re-examining the Association Between E-Cigarette Use and Myocardial Infarction: A Cautionary Tale. American journal of preventive medicine, 61(4), 474–482. https://doi.org/10.1016/j.amepre.2021.05.003 | ||
===2021: Increased Expression of Proatherogenic Proteins in Immune Cell Subtypes in Tobacco Cigarette Smokers But Not in Electronic Cigarette Vapers=== | ===2021: [https://www.sciencedirect.com/science/article/pii/S0828282X21002518 Increased Expression of Proatherogenic Proteins in Immune Cell Subtypes in Tobacco Cigarette Smokers But Not in Electronic Cigarette Vapers]=== | ||
*In this study, we showed that tobacco cigarette smoking, but not electronic-cigarette vaping, is associated with increased expression of major proteins in the toll-like receptor 4 (TLR4) inflammasome-interleukin (IL)-6 signalling axis in monocyte subtypes and T cells. | |||
*These findings implicate the non-nicotine, pro-oxidant toxicants in tobacco cigarette smoke as instigators of increased expression of key proteins in the TLR4-inflammasome-IL-6 axis that contribute to atherogenesis. | |||
*These data support additional investigations into the role of ECIGs as part of a harm reduction strategy for adults addicted to TCIGs who are unwilling or unable to quit. | |||
*"proatherogenic" = promoting fatty plaques in the arteries (which is bad) | |||
*Acknowledgement: This work was supported by the Tobacco-Related Disease Research Program under the contract number TRDRP 28IR-0065 (H.R.M.), by Univeristy of California Office of the President under the contract number R00RG2749 Emergency COVID-19 Research Seed Funding (H.R.M.), and by the National Institutes of Health National Center for Advancing Translational Science University of California Los Angeles Clinical and Translational Science Institute grant number L1TR001881. This work was also supported in part by National Institutes of Health grants R01AG059501, R03AG059462 (T.K.). The flow cytometry machine used in the study was purchased through the University of California Los Angeles Center for AIDS Research (P30AI28697) grant. | |||
*Citation: Kelesidis, T., Zhang, Y., Tran, E., Sosa, G., & Middlekauff, H. R. (2021). Increased Expression of Proatherogenic Proteins in Immune Cell Subtypes in Tobacco Cigarette Smokers But Not in Electronic Cigarette Vapers. The Canadian journal of cardiology, 37(8), 1175–1180. https://doi.org/10.1016/j.cjca.2021.05.006 | |||
===2020: Expression of Key Inflammatory Proteins Is Increased in Immune Cells From Tobacco Cigarette Smokers But Not Electronic Cigarette Vapers: Implications for Atherosclerosis=== | ===2020: Expression of Key Inflammatory Proteins Is Increased in Immune Cells From Tobacco Cigarette Smokers But Not Electronic Cigarette Vapers: Implications for Atherosclerosis=== | ||
edits